106 related articles for article (PubMed ID: 1489005)
21. Oxalic Acid as a uremic toxin.
Mydlík M; Derzsiová K
J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
[TBL] [Abstract][Full Text] [Related]
22. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the effects of muzolimine and furosemide in patients with end-stage renal failure on chronic dialysis.
Schmidt P; Loew D; Dycka J; Kopsa H; Balcke P; Zazgornik J; Deutsch E
Eur J Clin Pharmacol; 1981; 20(1):23-6. PubMed ID: 7308268
[TBL] [Abstract][Full Text] [Related]
24. Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study.
Janousek R; Krajina A; Peregrin JH; Dusilova-Sulkova S; Renc O; Hajek J; Dvorak K; Fixa P; Cermakova E
Cardiovasc Intervent Radiol; 2010 Feb; 33(1):61-6. PubMed ID: 19830486
[TBL] [Abstract][Full Text] [Related]
25. [The diuretic activity of bumetanide in a controlled comparison with furosemide in patients with various degrees of impaired renal function (author's transl)].
Kampf D; Baethke R
Arzneimittelforschung; 1980; 30(6):1015-8. PubMed ID: 7191261
[TBL] [Abstract][Full Text] [Related]
26. Renal effects of added low-dose dopamine in acute heart failure patients with diuretic resistance to natriuretic peptide.
Kamiya M; Sato N; Nozaki A; Akiya M; Okazaki H; Takahashi Y; Mizuno K; Shimizu W
J Cardiovasc Pharmacol; 2015 Mar; 65(3):282-8. PubMed ID: 25748698
[TBL] [Abstract][Full Text] [Related]
27. Step-dose of muzolimine at different stages of chronic renal failure: comparison with furosemide.
Morachiello P; Coli U; Landini S; Fracasso A; Righetto F; Scanferla F; Bazzato G
Z Kardiol; 1985; 74 Suppl 2():115-20. PubMed ID: 4002784
[TBL] [Abstract][Full Text] [Related]
28. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure.
Boesken WH; Kult J
Clin Nephrol; 1997 Jul; 48(1):22-8. PubMed ID: 9247774
[TBL] [Abstract][Full Text] [Related]
29. Effect of furosemide oral solution versus furosemide tablets on diuresis and electrolytes in patients with moderate congestive heart failure.
Cohen N; Golik A; Dishi V; Zaidenstein R; Weissgarten J; Averbukh Z; Modai D
Miner Electrolyte Metab; 1996; 22(4):248-52. PubMed ID: 8807629
[TBL] [Abstract][Full Text] [Related]
30. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
31. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.
Paterna S; Parrinello G; Cannizzaro S; Fasullo S; Torres D; Sarullo FM; Di Pasquale P
Am J Cardiol; 2009 Jan; 103(1):93-102. PubMed ID: 19101237
[TBL] [Abstract][Full Text] [Related]
32. [Effect of furosemide on water and sodium excretion in apparently normal infants].
López Uriarte A; Sánchez Burgos J; Santos Atherton D
Bol Med Hosp Infant Mex; 1976; 33(3):693-8. PubMed ID: 1275971
[TBL] [Abstract][Full Text] [Related]
33. Diuretic effect and pharmacokinetic data observed at different stages of chronic renal failure with 240 mg of muzolimine.
Baumelou A; Singlas E; Ritter W; Merdjan H; Martre H; Brouard R; Chickh-Touami C; Patte R
Z Kardiol; 1985; 74 Suppl 2():88-91. PubMed ID: 4002810
[TBL] [Abstract][Full Text] [Related]
34. High-dose furosemide in the treatment of refractory congestive heart failure.
Gerlag PG; van Meijel JJ
Arch Intern Med; 1988 Feb; 148(2):286-91. PubMed ID: 3341836
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamic effects of furosemide in patients with liver cirrhosis.
Traeger A; Häntze R; Penzlin M; Krombholz B; Reinhardt M; Keil E; Jorke D
Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):129-33. PubMed ID: 3997298
[TBL] [Abstract][Full Text] [Related]
36. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
Majumdar SR; Kjellstrand CM; Tymchak WJ; Hervas-Malo M; Taylor DA; Teo KK
Am J Kidney Dis; 2009 Oct; 54(4):602-9. PubMed ID: 19535188
[TBL] [Abstract][Full Text] [Related]
37. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
38. An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats.
Schnackenberg CG; Merz E; Brooks DP
Br J Pharmacol; 2003 Aug; 139(8):1383-8. PubMed ID: 12922924
[TBL] [Abstract][Full Text] [Related]
39. [Furosemide effects in patients with chronic renal insufficiency].
Sperschneider H; Stein G; Traeger A; Keil E
Z Gesamte Inn Med; 1984 Jun; 39(11):261-5. PubMed ID: 6475170
[TBL] [Abstract][Full Text] [Related]
40. [Effects of furosemide in patients with acute renal failure. Decrease of resort to dialysis methods].
Beaufils F; de Myttenaere S; Rohan J; Chapman A
Nouv Presse Med; 1972 Apr; 1(16):1073-8. PubMed ID: 5035863
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
